Letrozol Stada (Letrozole)

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By inhibiting this conversion, systemic estrogen concentrations fall, depriving estrogen‑dependent breast cancer cells of a key growth signal, thereby slowing proliferation and potentially inducing cell death.

The prescribed dose of Letrozol Stada is determined by the treating physician based on the patient’s clinical condition. In many treatment protocols, a common starting dose is 2.5 mg taken once daily, but the exact regimen should always follow the prescriber’s instructions.

Letrozol Stada is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may pass into breast milk and affect the infant.

To request Letrozol Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Letrozole is a non‑steroidal aromatase inhibitor, similar to anastrozole but generally considered more potent on a milligram‑per‑milligram basis. Unlike the steroidal inhibitor exemestane, letrozole binds reversibly to aromatase. All three lower estrogen levels, but differences in potency, side‑effect profile and drug‑interaction potential may influence the choice of therapy.

Letrozol Stada should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Letrozol Stada is taken orally, usually as a single tablet swallowed whole with a glass of water. It can be taken with or without food, but consistency in relation to meals helps maintain stable drug levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include severe liver injury, significant bone loss leading to fractures, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Rarely, life‑threatening allergic reactions may occur. Patients should be monitored regularly for signs of these conditions and report any concerning symptoms promptly.

Letrozol Stada is contraindicated in premenopausal women, pregnant or breastfeeding individuals, and patients with known hypersensitivity to letrozole or any tablet excipients. It should also be avoided in patients with severe hepatic impairment unless the prescriber determines that benefits outweigh the risks.